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Background: The incidence of adenocarcinoma of the esophagogastric junction is increasing. This study aims to
evaluate the clinicopathological features of Chinese patients with adenocarcinoma of the esophagogastric junction
and to define prognostic factors.
Methods: We retrospectively reviewed a database of 382 consecutive patients with adenocarcinoma of the
esophagogastric junction at the First Affiliated Hospital of Xi’an Jiaotong University from January 2005 to March
2010. All patients were classified according to the Siewert’s classification and staged according to the latest edition
of the American Joint Committee on Cancer categories.
Results: Six of the 382 patients had type I adenocarcinoma, 220 had type II, and 156 had type III. There was no
significant difference in the overall survival of different Siewert subtypes. According to the multivariate analysis,
pathological lymph node stage, age, and the existence of lymphovascular invasion were the independent factors of
prognosis of adenocarcinoma of the esophagogastric junction following surgery.
Conclusions: On the data, the distribution of the three types of tumor was found to be different from that
reported in Western countries. Lymph node metastasis, lymphovascular invasion, and age were significant and
independent factors for poor prognosis after R0 resection for adenocarcinoma of the esophagogastric junction.
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In Western countries, there has been a dramatic increase
in the incidence of adenocarcinomas of the esophagogastric
junction (AEG). On the other hand, Eastern countries have
not experienced such an increase [1-4]. The current Inter-
national Union against Cancer (UICC) TNM classification
of malignant tumors is the first to define the classification
of adenocarcinomas of the esophagogastric junction.
According to the UICC, a tumor with an epicenter
within 5 cm of the esophagogastric junction (EGJ) and
extension into the esophagus, is classified and staged
according to the esophageal scheme. Tumors with an
epicenter greater than 5 cm from the EGJ or those within
5 cm of the EGJ without extension into the esophagus were
staged using the gastric carcinoma scheme [5]. In 1996,
Siewert and Stein published a classification of AEG which
was later approved at the second International Gastric* Correspondence: dangchengxue@yahoo.com.cn
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reproduction in any medium, provided the orCancer Congress in Munich in April 1997. According
to this classification, a tumor could be identified into
three types (type I, type II, and type III) in terms of the
anatomic location of the tumor center. Specifically, type I
is adenocarcinoma of the distal esophagus with the
epicenter located within 1 cm and 5 cm above the
anatomic EGJ; type II is true carcinoma of the cardia with
the tumor epicenter within 1 cm above and 2 cm below
the EGJ; type III is subcardial carcinoma with the tumor
epicenter between 2 and 5 cm below the EGJ [6]. Before
the UICC classification, type I was usually classified with
the esophageal scheme, and types II and III were classified
with the gastric carcinoma scheme [4,7,8].
In China, institutes seldom focus on this special
anatomic location, they often treat AEG as distal esophagus
or proximal gastric cancer. Therefore, this study analyzes
the clinicopathological characteristics and factors which
could affect overall survival.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of patients with adenocarcinoma
of the esophagogastric junction
Siewert classification Type I Type II Type III P value
(n = 6) (n = 220) (n = 156)
Age (years) 65.5±9.7 62.4±8.6 63.0±8.4 >0.05
Male:Female 6:0 6.3:1 6.1:1 >0.05
Tumor size (mm) 35.0±7.7 40.8±16.8 64.7±27.8 <0.01
Esophageal invasion (mm) 28.3±16.3 10.7±9.1 6.0±7.2 <0.01
Approaches <0.01
Transhiatal 2 169 136
Transthoracic 2 42 17
Transthoracoabdominal 2 9 2
Resection range <0.01
Total gastrectomy 0 6 15
Proximal gastrectomy 6 214 141
TNM stage >0.05
Stage I 0 24 9
Stage II 1 54 37
Stage III 5 142 110
Histopathological grade >0.05
G1/2 3 115 65
G3/4 3 105 91
Neoadjuvant chemotherapy 0 11 3 >0.05
Adjuvant chemotherapy 1 40 16 >0.05
Pattern of recurrence >0.05
Haematogenous 4 57 44
Local recurrence 1 38 29
Nodal recurrence 1 18 17
Peritoneal recurrence 0 2 3
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Patients
We retrospectively reviewed a database of 382 consecutive
patients of distal esophageal adenocarcinoma, adenocarci-
noma of the cardia, and proximal gastric adenocarcinomas
at the First Affiliated Hospital of Xi’an Jiaotong University
from January 2005 to March 2010. The retrospectively
collected data of these patients included demographic
parameters, histopathologic tumor characteristics, operation
methods, and survival time. The median follow-up for
the cohort was 26.7 months (range 1–75 months). We
measured the distance from the cardiac dentate line to the
oral top of the tumor base on the CT scanning, gastroscopy,
operative, and pathological findings, and defined it as the
length of esophageal invasion [9]. The eligibility criteria
were: i) patients without a history of prior malignancy
or recurrence of the tumor, ii) patients who underwent
potentially curative surgery.
Classification
All patients were classified according to Siewert’s classi-
fication and the AEGs were staged according to both the
esophageal and gastric schemes of the seventh edition of
the American Joint Committee on Cancer (AJCC) and
UICC of malignant tumors using the histopathologic
postoperative pTNM categories [5,10]. Therefore, AEGs
with an epicenter within 5 cm of the EGJ and extension
into the esophagus were classified and staged according to
the esophageal scheme; AEGs which had an epicenter
within 5 cm of the EGJ without extension into the esopha-
gus were staged using the gastric carcinoma scheme.
Statistical analysis
Statistical analyses were performed using SPSS 13.0.
Consecutive data were presented as the mean ± standard
deviation (SD). Categorical data were compared by a χ2
test or Fisher’s exact test. The means of the two groups
were assessed with rank-sum test or t-test. Cumulative
survival rates were generated by the Kaplan-Meier method.
Survival curves and univariate significant factors were
compared with the log-rank test. Cox proportional hazard
models were constructed to investigate multivariable
relationships of covariates with survival. All statistical tests
were two-sided, and P values <0.05 were considered to be
statistically significant.
Results and discussion
Patient and pathological characteristics
There were 330 males and 52 females in the 382 patients
who had undergone curative radical resections (R0).
Extended lymphadenectomy (two-field lymphadenectomy)
was performed for type I adenocarcinomas and a systematic
D2 lymphadenectomy was performed for type II and type
III tumors. The ratio of male to female was 6.35:1 and theaverage age was 62.7 years old. Six of the 382 patients had
type I (1.6%) adenocarcinomas, 220 had type II (57.6%),
and 156 had type III (40.8%) adenocarcinomas.
The patient characteristics according to different Siewert
types are presented in Table 1. There were no significant
differences in age and gender among the subtypes. The
tumor size of type III (64.7 mm) was significantly larger
than that of type II (40.8 mm) and type I (35.0 mm). The
esophageal invasion length was significantly different
between the three types; it was longer for type I than for
types II and III and the longest esophageal invasion was
50 mm in type I. Proximal gastrectomy with distal
esophagectomy via laparotomy was more common in
these patients than other approaches.
The transthoracic technique was used the most for type I
(66%) tumors, which included 50% of trans-left-thoracic
and 50% of transthoracoabdominal approaches. In contrast,
the transhiatal approach was common in type II and
type III, the rates were 77% and 87%, respectively. For
Figure 1 Survival curves of Siewert types. No significant difference
in overall survival by subtypes was observed.
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gastrectomy with distal esophagectomy (100%), whereas
the rates of total gastrectomy in types II and III were 3%
and 10%, respectively. According to the T category, N
category, and AJCC stage, the distribution of the propor-
tion in different Siewert types did not show a significant
difference. According to the histopathological grade,
the distribution of the proportion of well or moderately
differentiated tumors was significantly higher in type II
than in type III.
The average lymph node resection was 13.3±6.7 for
type I, 13.5±7.1 for type II, and 15.1±7.4 for type III; 278
(72.8%) of the patients had lymph node metastasis. For
those patients, the most common sites of nodal involve-
ment were the paracardia (67.3%), lesser curvature (66.5%),
greater curvature (12.9%), paraesophageal (2.9%), and left
gastric artery (2.5%). In spite of the type I tumor, the
frequency of lymph node metastasis was higher in patients
with type II tumors than with type III tumors.
There was no significant difference in the rate of patients
who received perioperative chemotherapy. The pattern of
recurrence indicated that the most frequent type of recur-
rence was haematogenous and the most frequent site was
the liver, followed by local recurrence and nodal recurrence;
peritoneal recurrence was relatively infrequent. The pattern
of recurrence in each subgroup did not show a significant
difference. As for lymphovascular invasion, the rate was
higher in T3-4 tumors (9.3%) than in T1-2 tumors (2.0%).
Overall survival
No significant difference was observed in the overall
survival of different Siewert subtypes (P = 0.124; Figure 1).
After pairwise comparison, type I versus type II was
P = 0.480, type I versus type III was P = 0.288, and
type II versus type III was P = 0.200. Kaplan-Meier
survival analysis was used to assess ten other prognostic
factors: age (<65 versus ≥65 years), gender, tumor max-
imal size (<50 mm versus ≥50 mm), esophageal invasion
(positive versus negative), T stage, N stage, histopathological
grade, lymphovascular invasion, operation methods, and
combined organ resection. Univariate analysis revealed
eight factors as having significant differences associated
with the overall survival of AEG after surgery, namely age,
tumor maximal size, total gastrectomy, combined organ
resection, AJCC T stage, N stage, histopathological grade,
and lymphovascular invasion. Multivariate analysis of these
eight factors was performed to adjust the effects of covari-
ates in a multivariate Cox proportional hazards model
(Table 2). In this analysis, pathological lymph node stage,
age, and the existence of lymphovascular invasion were
the independent factors of prognosis of AEG following
surgery. Therefore, it can be concluded that: i) patients
who are older than 65 years old have a worse prognosis
than those under 65 years old; ii) the greater the lymphnode metastasis the lower overall survival rate (Figure 2);
iii) patients with negative lymphovascular invasion have
a better 5-year survival rate than those with positive
lymphovascular invasion (Figure 3).
Discussion
In this single-institution series of 382 AEG patients in
China, the proportions of types I, II, and III carcinomas
were 1.6%, 57.6%, and 40.8%, respectively. This showed a
higher distribution of types II and III AEG in China
compared with Western countries, but not with other
Eastern nations [3,4,8,9]. Hosokawa et al. [9] found that, in
Japan, 10 of 179 AEGs were type I patients; a retrospective
analysis in Taiwan [8] did not reveal even one type I patient
in 10 years. The lower frequency of type I AEG in Eastern
countries may be explained by a lower prevalence of
gastroesophageal reflux disease, a lower distribution of
obese people, and a higher rate of Helicobacter pylori
infection [11-13]. After R0 resection, the 5-year survival
rates were 0% for type I, 29% for type II, and 23% for type
III tumors. Although our data only included R0 resection,
the outcomes seem worse than other prior reports. The
0% 5-year survival rate for type I patients was mainly due
to most of the data being collected from stage III patients.
The proportion of stage III AEG was 67.3%, which was
higher than in other reports [8,14]; 83.3% of type I AEG
was stage III. There was no significant difference in age
and gender among the three types of AEG. However,
according to the clinicopathological features, the three
types were different; type III were more aggressive than
type II, type III tumors were larger and deeper, with a
Table 2 Univariate and multivariate predictors of overall
survival










Type I, II, III >0.05 0.788–1.548
Age (years)
<65 or ≥65 <0.05 1.041–2.115 <0.05 1.051–2.206
Gender
Male or Female >0.05 0.628–1.707
Tumor maximal size (mm)
<50 or ≥50 <0.01 1.528–3.194 >0.05 0.878–1.920
Esophageal invasion
Positive or Negative >0.05 0.662–1.580
T category
T1-2 or T3-4 <0.01 2.085–7.655 >0.05 0.947–6.366
N category
N0, N1, N2, N3 <0.01 1.702–2.401 <0.01 1.611–2.406
Histopathological grade
G1/2 or G3/4 <0.01 1.367–2.416 >0.05 0.909–1.984
Combined organ resection
With or Without <0.01 1.285–3.707 >0.05 0.811–2.410
Lymphovascular invasion
Positive or Negative <0.05 1.117–3.042 <0.05 0.266–0.878
Resection range
Total gastrectomy





Figure 2 Survival curves of lymph node metastasis. There was a
significant difference between N categories in patients.
Figure 3 Survival curves of lymphovascular invasion. Patients
whose lymphovascular invasion was negative had a significantly
better 5-year survival rate than those were positive.
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that type III carcinomas centered 2–5 cm below the EGJ
might infiltrate the EGJ and are more difficult to detect
early [9].
In the present study, the majority of patients with type
II and III carcinomas underwent proximal gastrectomy
with distal esophagectomy via an abdominal approach.
In recent years, total gastrectomy has emerged as the
standard procedure to treat types II and III AEG. However,
in our hospital, most surgeons perform the operation
ensuring a large enough non-infiltrating margin (5 cm),
which might explain why proximal gastrectomy was
performed in most patients. Only those who had large-
sized tumors received a total gastrectomy in order to
obtain a negative surgical margin. Thus, there is a connec-
tion between the large tumor size, more aggressivecharacteristics, and total gastrectomy, leading to a worse
5-year survival rate for total gastrectomy compared to
proximal gastrectomy. Further, multivariate analysis
(surgical procedure and tumor size) indicated that the
surgical procedure is not the crucial factor (P = 0.106)
while the survival benefits between different tumor size
are significantly different (P <0.001). Thoracic surgeons
Zhang et al. World Journal of Surgical Oncology 2013, 11:155 Page 5 of 6
http://www.wjso.com/content/11/1/155were more likely to select the transthoracic approach to
treat AEG; however, for type III patients, this might cause
an insufficient lymphadenectomy. Therefore, an abdominal
approach is more suitable for type III AEG.
The UICC sixth TNM classification did not include a
criterion for AEG, which caused a confusion regarding
the staging of AEG according to esophageal or gastric
scheme criteria. Previous studies have usually chosen to
treat type I as esophageal scheme, and type II and III as
gastric scheme. The UICC seventh TNM classification
has now defined the staging scheme criteria for AEG.
Here we classified and staged the 382 AEG according to
the latest criteria. It is noted that type I did not change
staging scheme while some type II and III AEG changed
from the gastric to the esophageal scheme; further, some
tumors which extend into the esophagus are staged
according to the esophageal scheme while they might
originate from the gastric mucosa. AEGs might have
different biological properties compared with genuine
gastric and genuine esophageal cancers [15]. Therefore,
further studies are required in order to ascertain if the
latest scheme is suitable or not.
Multivariate analysis showed that lymph node metastasis,
age, and the existence of lymphovascular invasion were
independent prognostic indicators for AEG after R0 resec-
tion. Among the three factors, we demonstrated that
lymph node metastasis was the strongest poor prognostic
factor (odds ratio = 2.0). Our data showed that lymph
nodes around the cardia, the lesser curvature of the
proximal stomach, and along with the greater curvature of
the proximal stomach had the highest rate of metastasis.
This means that an appropriate resection of abdominal
lymph nodes is very important to AEG patients [8],
especially for the thoracic approach. In addition, although
lymphovascular invasion was thought to precede or occur
coincidently with lymph node metastasis [16], we found
that in the advanced disease, lymphovascular invasion
occurred at a considerably high rate. As a prognostic
factor, the ratio of lymphovascular invasion increased
with deeper carcinoma invasion and larger size causing
a poor prognosis. Patients older than 65 years old had a
poorer prognosis than younger patients. While most
studies in the West indicated that lymph node metastasis
and Siewert types were prognostic factors, they found type
I patients had a significantly better overall survival rate
than type II and III patients [17,18]. This might be partly
due to a high distribution of types II and III AEG in
Eastern countries compared with Western countries. The
low incidence of type I AEG might cause some misleading
or confusion in the overall survival rate.
Conclusions
The distribution of the three types of tumor was found to
be different from that reported in Western countries.Lymph node metastasis, lymphovascular invasion, and
age were significant and independent factors of poor
prognosis for AEG after R0 resection.
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